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Abstract
Objective—Because studies suggest that ultraviolet radiation (UVR) modulates myositis
phenotype and Mi-2 autoantigen expression, we conducted a retrospective investigation to
determine if UVR may influence the relative prevalence of dermatomyositis and anti-Mi-2
autoantibodies in the United States.
Methods—We assessed the relationship between surface UVR intensity in the state of residence
at the time of onset with the relative prevalence of dermatomyositis and myositis autoantibodies in
380 myositis patients from referral centers in the U.S. Myositis autoantibodies were detected by
validated immunoprecipitation assays. Surface UVR intensity was estimated from UV index data
collected by the U.S. National Weather Service.
Results—UVR intensity was associated with the relative proportion of patients with
dermatomyositis (odds ratio [OR] 2.3, 95% confidence interval [CI] 0.9–5.8) and with the
proportion of patients expressing anti-Mi-2 autoantibodies (OR 6.0, CI 1.1–34.1). Modeling of
these data showed that these associations were confined to women (OR 3.8, CI 1.3–11.0 and OR
17.3, CI 1.8–162.4, respectively) and suggests that gender influences UVR effects on autoimmune
disorders. Significant associations were not seen in men, nor were UVR levels related to the
presence of anti-synthetase or anti-signal recognition particle autoantibodies.
Conclusion—This first study of the distribution of myositis phenotypes and UVR exposure in
the United States showed that UVR may modulate the clinical and immunologic expression of
autoimmune disease in women. Further investigation of the mechanisms by which these effects are
produced may give insights into pathogenesis and suggest therapeutic or preventative strategies.
Current evidence suggests that autoimmune diseases result from environmental exposures in
genetically susceptible individuals and ultraviolet radiation (UVR) is an environmental
exposure of increasing interest (1). Beyond UVR’s recognized association with skin cancer
are other immunomodulatory effects possibly related to the development of immune-
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mediated disorders (2). UVR can promote surface expression of adhesion molecules, alter
cytokine expression and decrease resistance to infections. UVR also upregulates the
expression, alters the cellular location and induces immune responses to autoantigens. UVR
exposure is important to calcium metabolism through effects on metabolically active vitamin
D. Moreover, UVR is associated with increases in the clinical expression of conditions
characterized by photosensitive rashes, such as lupus and dermatomyositis, in which patients
have a lower UV minimal erythemal dose threshold compared to normal controls (3).
Furthermore, studies suggest that UVR regulates levels of the dermatomyositis-specific
Mi-2 autoantigen via protein translational effects (4).
The idiopathic inflammatory myopathies (IIM) are acquired systemic autoimmune
conditions that share chronic muscle weakness due to chronic muscle inflammation. The two
major clinical groups, dermatomyositis (DM) and polymyositis (PM), are distinguished by
the presence of photosensitive pathognomonic rashes in DM (5). These two forms of IIM
share some genetic risk factors but differ in others and appear to have distinct pathogeneses
(5). Categorizing myositis patients by the presence or absence of myositis-specific
autoantibodies (MSA) results in more homogenous groups in terms of epidemiology,
clinical presentations, genetics and prognoses (5). MSA include autoantibodies directed
against aminoacyl-tRNA synthetases (anti-synthetases), the signal recognition particle (anti-
SRP), and autoantibodies that react with a 240 kD protein called chromodomain helicase
DNA binding protein 4 (anti-Mi-2).
To understand possible genetic and environmental risk and protective factors for myositis
within the U.S., we studied myositis referral populations to determine the relative prevalence
of the clinical and immunologic phenotypes. Because specific photosensitive rashes
uniquely characterize DM, and given recent associations of UVR with DM and anti-Mi-2
autoantibodies (6), we focused on assessing if such phenotypic differences may be related to
UVR exposure. This first U.S. analysis of myositis phenotypes in different regions has
revealed geographic variations in the clinical and immunologic expression of disease in
women that are strongly predicted by ambient UVR intensity.
PATIENTS AND METHODS
Clinical and serologic evaluations
A cross-sectional retrospective study of the state of residence at time of onset of myositis
was conducted in PM and DM patients from referral centers. Clinical data and sera samples
were collected with ethics committee approval and informed consent. DM was distinguished
from PM by Gottron’s papules, Gottron’s sign or heliotrope rashes. Consecutive patients
who met criteria for definite or probable PM or DM (5), who had data available regarding
their state of residence at myositis onset, and for whom myositis autoantibodies had been
determined by the Oklahoma Medical Research Foundation, Oklahoma City, OK, were
identified from referral centers. The participating centers were: the NIH Clinical Center,
Bethesda, MD (N= 218); University of Pittsburgh, Pittsburgh, PA (N=74); the University of
Texas, Houston, TX (N=35); and the University of Oklahoma, Oklahoma City, OK (N=8).
Another group of myositis patients (n= 45), recruited from other centers in the US (7), were
also included in our study. Of the total 380 IIM patients studied (73% of whom were
female), 67% were European American, 28% were African American, 2% were Hispanic
American, 2% were Asian American and 1% was other ethnic groups. Due to the small
numbers in certain ethnic groups, and based upon skin gradients and sensitivity to UVR (8),
for our analyses we grouped European Americans, Hispanic Americans and Asian
Americans together as non-African Americans.
Love et al. Page 2
Arthritis Rheum. Author manuscript; available in PMC 2010 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Determination of UVR levels
UVR levels were estimated by the UV index, which was obtained from the National
Weather Service UV Index Cities Forecast Archive
(ftp://ftp.cpc.ncep.noaa.gov/long/uv/cities/). The UV index, a linear variable, is an
integration of the UV action spectrum-weighted UVA and UVB irradiances over the 290 to
400 nm range. Because only state locations at time of onset were available for the subjects,
an overall average state UV index was calculated from the average annual UV index for
2001 assigned to the state (states with multiple recording sites received the average of the
sites’ values).
Statistical Methods
Because accrual of all myositis patients in each area was not possible, geographic variation
in the incidence of myositis could not be validly explored. We instead modeled the relative
odds for DM using logistic regression (9), modeling the logarithm of the odds for DM
versus PM as dependent on possible predictors, which included gender and race. Because of
prior evidence that UVR levels were related to the proportion of DM at referral centers (6),
we ascertained UV index levels by state and modeled the influence of UVR on the myositis
phenotype. Due to the absence or relatively small numbers of subjects in some of the states,
we evaluated similar associations using aggregated state data in the seven geoclimatic
regions of the US. We also modeled the logarithm of the odds for autoantibody-positivity as
a function of the same predictors, using logistic regression. All UVR associations are with
the logit of the proportion of DM or the proportion of autoantibodies. All logistic analyses
were done using the Generalized Linear Interactive Modeling system package (release 3.77,
The Numerical Algorithms Group, Inc., Lisle, IL) and all p values cited are two-sided.
RESULTS
The phenotypes and demographic features of the 380 IIM patients in this study were similar
to those reported in other investigations (10). PM accounted for 53% (n=202) of the patients.
MSAs were seen in 45% (n=172): of these anti-synthetase autoantibodies were seen in 34%
of patients (36% in PM and 31% in DM). Anti-SRP autoantibodies (n=21) were found
exclusively in PM patients and anti-Mi-2 autoantibodies (n=23) were found only in DM
patients. Significant differences were noted in the ethnic distributions in the clinical and
serologic groups. African Americans (n=105) were found to have relatively more PM (66%)
than DM compared to non-African Americans, of which only 48% had PM (p=0.002).
Ethnic differences were also noted in those with anti-SRP autoantibodies (86% of whom
were African American, p< 0.0000005). There were no significant gender differences,
however, in the clinical or autoantibody groups.
At the time of myositis onset patients resided in 37 states, which were categorized into seven
regions based on shared geoclimatic factors (Table 1). The possible effects of UVR on
clinical group and myositis-specific immune responses in these populations were assessed in
the total IIM population and in gender and ethnic groups (Table 2). The UV index was
positively associated with the proportion of DM patients in the total IIM population, but this
did not reach significance at the 0.05 level (OR 2.3, CI 0.9–5.8, p=0.07). The proportion of
IIM patients with anti-Mi-2 autoantibodies was significantly associated with the UV index
(OR 6.0, CI 1.1–34.1, p=0.05). There were no significant associations between UVR
intensity and the proportion of IIM patients with anti-synthetase or anti-SRP autoantibodies,
or those without any MSAs (data not shown).
Surprisingly, the UVR effects above appeared to be the result of associations in women (OR
3.8, CI 1.3–11.0, p=0.014 for the association of the UV index with the proportion of DM,
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and OR 17.3, CI 1.8–162.4, p=0.012 for the association of the UV index with the proportion
of anti-Mi-2 autoantibodies). These associations in women were stronger in non-African
Americans than African Americans, but the fitted linear relationships were similar and the
smaller sample sizes in African Americans limited the power to detect possible associations
(Table 2). Nonetheless, there was no evidence for such relationships with the UV index in
men, whether African American or not. Since some states had no or relatively few patients,
these associations were displayed graphically after aggregating state data into seven regions
of the U.S. and analyses of these data gave similar results (Figure 1).
DISCUSSION
Variations in IIM clinical features and serologic expression were noted across U.S.
geographic regions and were found to correlate with the intensity of UVR. These findings
suggest that gradients of DM and anti-Mi-2 autoantibodies exist in the U.S., as they do
elsewhere, and are related to UVR intensity (6). This is the first investigation to show
evidence of a gender influence on UVR associations in autoimmune disorders.
There were certain limitations in the approaches we used that could have influenced our
results. Because data to assess the population-based incidence or prevalence of DM and PM
at each location are not available, we used information from referral centers that evaluate
myositis patients in the region as a practical approach. It is likely that myositis patients seen
at referral centers are not representative of the larger myositis population. While we are not
aware of any systematic referral biases based on autoantibodies or clinical phenotype to
these centers that could account for these findings, referral bias remains a possibility.
Another limitation is that we had only state of residence at the time of myositis onset
available to us for this study, and UVR intensities can vary considerably from one part of a
state to another. Environmental exposures or factors other than UVR may also account for
these findings. Moreover, we have no way to take individual-level exposure, or differences
in UVR exposure at different locations over time, into account. Finally, the use of personal
photoprotective measures, as well as occupations and avocations, can greatly influence an
individual’s cumulative UVR exposure. Future investigations should address these issues
and possible alternative explanations.
The significant associations of ethnic groups with the clinical and autoantibody phenotypes
in IIM are also potentially revealing in terms of pathogenesis. While known risk factors for
these phenotypes include selected polymorphisms in immune response genes, they do not
fully account for these differences. Of course, the increased skin pigmentation in African
Americans could alter their circulating levels of vitamin D and also reduce the damaging
effects of UVR, thus limiting UVR-induced alterations that may lead to DM and anti-Mi-2
autoantibodies (11). It is not known why African Americans are more likely to produce anti-
SRP autoantibodies, but since these do not seem to be influenced by UVR, mechanisms
other than skin pigmentation are likely responsible.
The reasons for the female gender effects seen in this investigation remain unclear, although
some studies have suggested differential impacts of UVR in males and females. It is known
that 17β-estradiol prevents UVB-induced suppression of the contact hypersensitivity
response caused by immunosuppressive cytokines produced by keratinocytes in mice (12).
Also, men were immunosuppressed by solar-simulated UVR doses three times lower than
those required to immunosuppress women (13). Since these studies imply a greater impact
of UVR on immune effects in men than women, other mechanisms would need to be
operative to potentially explain how UVR preferentially results in the development of DM
and anti-Mi-2 autoantibodies in women.
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How UVR might result in DM or anti-Mi-2 autoantibodies is also unknown, however, many
potential mechanisms are suggested from the published UVR effects on immunosuppression
and promotion of autoimmunity (14). UVR induces a cascade of events involving type I
interferon signatures, which have been associated with DM. Additionally, there is a wide
range of effects of UVR involving many other immune networks involved in the
pathogenesis of myositis, including alterations in stress proteins, IL-1, IL-6, TNFα, nuclear
factor (NF)-kappaB and adhesion molecule pathways (15). Another recent finding is the
rapid upregulation of Mi-2 antigen following UVR, which is mediated via more efficiently
translated messages and increased stability of the protein (4). Given these data, it is tempting
to speculate that the development of DM and DM-specific anti-Mi-2 autoantibodies, which
are associated with certain major histocompatibility loci, are related to UV-induced
increased expression of target autoantigens, combined with altered immune responses, in
genetically susceptible individuals. Alternatively, our data are consistent with the possibility
that UVR exposure, or a correlate of UVR exposure, is protective for the development of
PM. Understanding these mechanisms more fully, as well as the gender and ethnic
influences on them, should allow for insights into the pathogenesis of myositis and could
have implications for deciphering the causes of other autoimmune diseases.
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Figure 1.
Associations between the annual UV Index in seven U.S. regions and the proportion of
patients with dermatomyositis (DM) and anti-Mi-2 autoantibodies in each region. Modeling
of these data for all myositis patients based on state of residence showed a non-significant
trend for association between the UV index and the logit of the proportion of DM patients
(p=0.07, upper left panel), but a significant association with the logit of the proportion of
those with anti-Mi-2 autoantibodies (p=0.05, upper right panel). The data suggest that these
associations are driven by women (for DM, p=0.014, lower left panel; for anti-Mi-2
autoantibodies, p=0.012, lower right panel). Because no patients with anti-Mi-2
autoantibodies were in the Northwest region, this region is not represented in the right two
panels. The size of the circle representing each region is proportional to the number of
patients residing in that region at the time of myositis onset.
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Table 2
Gender and racial associations of the UV Index by state with the proportion of subjects with dermatomyositis
and with anti-Mi-2 autoantibodies*
Myositis groups Odds ratio (95% confidence interval) for development of:
Dermatomyositis (n=178) Anti-Mi-2 autoantibody (n=23)
All subjects 2.3 (0.9, 5.8) 6.0 (1.1, 34.1)
 Non-African Americans 3.2 (1.0, 9.8) 6.4 (0.8, 49.9)
 African Americans 2.4 (0.4, 13.1) 6.0 (0.2, 175.8)
 Females 3.8 (1.3, 11.0) 17.3 (1.8, 162.4)
  Non-African Americans 6.9 (1.7, 28.1) 37.1 (1.9, 713.1)
  African Americans 2.4 (0.4, 15.0) 4.4 (0.1, 129.0)
 Males 0.6 (0.1, 3.6) 1.1 (0.0, 27.3)
  Non-African Americans 0.6 (0.1, 4.4) 1.1 (0.0, 27.0)
  African Americans 0.3 (0.0, 117.4) Not calculable due to small numbers
*
Significant associations are bolded; the odds ratio is for the UV Index range across the U.S. states in the study
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